There will be new ESC heart failure guidelines and presentation of data from EMPEROR-Preserved and EMPEROR-Pooled, noted Rudolf de Boer, MD, PhD, of University Medical Center Groningen, the Netherlands.
Two highlights at this year’s ESC Congress 2021 will be new ESC heart failure guidelines and presentation of the EMPEROR-Preserved and EMPEROR-Pooled trial data, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
De Boer will be presenting “HFpEF Management: State of the Art SGLT2 Inhibitors,” on day 2 of ESC Congress 2021, this year’s virtual annual meeting of the European Society of Cardiology.
Transcript
What will be some of the biggest news to come out of ESC Congress 2021?
So, clearly, a few of the highlights of this meeting—much to my liking, I must say—have to do with heart failure. We will have the new ESC heart failure guidelines being presented. This, of course, is the absolute highlight of the meeting. It's very important; it's been 5 years. Two months ago or so we already saw a preview on what the pharmacological treatment algorithm looks like for heart failure with reduced ejection fraction, but now we will see that the whole guideline being presented is very important. I assume there will be interesting changes in device therapy, some diagnostics, clearly the use of SGLT2 [sodium-glucose cotransporter 2] inhibitors will be highlighted, and likely the use of sacubitril/valsartan will be prioritized. So I think there will be a number of important perspectives there.
A second highlight, in my humble opinion, is the presentation of the EMPEROR-Preserved and the EMPEROR-Pooled [trial results], because for the first time, we have a drug now that has shown efficacy over the full spectrum of left ventricular ejection fraction [LVEF]. So I'll be very interested to see if there is any interaction with LVEF or not. I hope for the latter because that means, as physicians, our lives are going to be substantially easier and we can just employ drugs without always thinking of EF.
With regards to COVID-19, I'm not entirely sure if there's a lot of news in this ESC meeting. We, of course, in the beginning of the pandemic, had seen quite disturbing data on how the heart was involved in COVID-19 infections, with very high rates of myocarditis and perimyocarditis. Later publications actually have negated these initial findings, and as it stands now, it seems that myocarditis is relatively rare. This, of course, is an important topic also because the use of COVID-19 vaccinations has also been associated, especially in young males, with the onset of myocarditis.
I guess the main issue with regards to COVID-19 care, for cardiology care, is that COVID-19 kind of pushes away all other important cares—albeit cardiovascular care, renal care, cancer care—because patients are hospitalized for such a long period. So this is more of an organizational issue that plays in in several countries in the Western world, including in the Netherlands; I believe also in the USA. Although in some countries to a lesser extent, for example, in Germany, it plays less in because there are many more ICU beds than in other countries. But that's an organizational issue.
It's a pity that, again, ESC is on the virtual scale and not live. That has to do with COVID-19, and I sincerely hope that next year it will be live again.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More